Catalyst Pharma Up 5% on Angelini Takeover

Catalyst Pharmaceuticals shares rose 5% on Monday after Bloomberg reported Angelini Pharma is exploring a potential acquisition.
Angelini Pharma, a family‑owned Italian drugmaker, is working with advisers to study the purchase of the US‑listed company.
The acquisition talks are at a preliminary stage, with Angelini reviewing multiple potential targets as part of its global expansion strategy.